Literature DB >> 18561579

How to justify enforcing a Ulysses contract when Ulysses is competent to refuse.

John K Davis1.   

Abstract

Sometimes the mentally ill have sufficient mental capacity to refuse treatment competently, and others have a moral duty to respect their refusal. However, those with episodic mental disorders may wish to precommit themselves to treatment, using Ulysses contracts known as "mental health advance directives." How can health care providers justify enforcing such contracts over an agent's current, competent refusal? I argue that providers respect an agent's autonomy not retrospectively--by reference to his or her past wishes-and not merely synchronically--so that the agent gets what he or she wants right now-but diachronically and prospectively, acting so that the agent can shape his or her circumstances as the agent wishes over time, for the agent will experience the consequences of providers' actions over time. Mental health directives accomplish this, so they are a way of respecting the agent's autonomy even when providers override the agent's current competent refusal.

Entities:  

Mesh:

Year:  2008        PMID: 18561579     DOI: 10.1353/ken.0.0001

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  4 in total

1.  Ulysses arrangements in psychiatric treatment: towards proposals for their use based on 'sharing' legal capacity.

Authors:  Phil Bielby
Journal:  Health Care Anal       Date:  2014-06

2.  Thwarting the Diseased Will: Ulysses Contracts, the Self and Addiction.

Authors:  Kirsten Bell
Journal:  Cult Med Psychiatry       Date:  2015-09

3.  Fluctuating capacity and advance decision-making in Bipolar Affective Disorder - Self-binding directives and self-determination.

Authors:  Tania Gergel; Gareth S Owen
Journal:  Int J Law Psychiatry       Date:  2015-05-02

4.  Involuntary mental health treatment in the era of the United Nations Convention on the Rights of Persons with Disabilities.

Authors:  Faraaz Mahomed; Michael Ashley Stein; Vikram Patel
Journal:  PLoS Med       Date:  2018-10-18       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.